Novartis’ remibrutinib met all the primary and secondary endpoints at 12 weeks in Phase III REMIX-1 and REMIX-2 trials in adults with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,